California Public Employees Retirement System Grows Position in Amneal Pharmaceuticals Inc (NYSE:AMRX)

California Public Employees Retirement System increased its holdings in shares of Amneal Pharmaceuticals Inc (NYSE:AMRX) by 17.8% in the third quarter, Holdings Channel reports. The firm owned 118,271 shares of the company’s stock after buying an additional 17,866 shares during the period. California Public Employees Retirement System’s holdings in Amneal Pharmaceuticals were worth $343,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of AMRX. Tower Research Capital LLC TRC lifted its position in Amneal Pharmaceuticals by 790.6% in the second quarter. Tower Research Capital LLC TRC now owns 7,766 shares of the company’s stock valued at $56,000 after buying an additional 6,894 shares during the last quarter. Bank of Montreal Can lifted its holdings in shares of Amneal Pharmaceuticals by 87.5% in the 2nd quarter. Bank of Montreal Can now owns 8,475 shares of the company’s stock worth $60,000 after acquiring an additional 3,954 shares during the last quarter. Meeder Asset Management Inc. lifted its holdings in shares of Amneal Pharmaceuticals by 1,176.2% in the 3rd quarter. Meeder Asset Management Inc. now owns 32,798 shares of the company’s stock worth $94,000 after acquiring an additional 30,228 shares during the last quarter. Nisa Investment Advisors LLC boosted its position in shares of Amneal Pharmaceuticals by 12,036.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 39,445 shares of the company’s stock worth $114,000 after purchasing an additional 39,120 shares during the period. Finally, Clearline Capital LP purchased a new position in shares of Amneal Pharmaceuticals during the 2nd quarter worth approximately $226,000. 35.80% of the stock is owned by hedge funds and other institutional investors.

Shares of AMRX stock opened at $3.71 on Friday. Amneal Pharmaceuticals Inc has a fifty-two week low of $2.27 and a fifty-two week high of $17.81. The company has a 50 day moving average price of $3.17 and a 200 day moving average price of $4.27. The stock has a market capitalization of $1.12 billion, a P/E ratio of 3.91, a price-to-earnings-growth ratio of 3.66 and a beta of 1.52. The company has a debt-to-equity ratio of 6.91, a quick ratio of 1.50 and a current ratio of 2.25.

Amneal Pharmaceuticals (NYSE:AMRX) last released its earnings results on Wednesday, November 6th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.13 by ($0.09). Amneal Pharmaceuticals had a positive return on equity of 23.17% and a negative net margin of 19.61%. The business had revenue of $378.30 million for the quarter, compared to analyst estimates of $403.90 million. During the same quarter last year, the company earned $0.28 earnings per share. Amneal Pharmaceuticals’s quarterly revenue was down 20.6% compared to the same quarter last year. On average, research analysts forecast that Amneal Pharmaceuticals Inc will post 0.26 EPS for the current fiscal year.

AMRX has been the topic of a number of research analyst reports. Svb Leerink lowered Amneal Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 7th. Guggenheim started coverage on Amneal Pharmaceuticals in a research note on Thursday, September 12th. They set a “sell” rating and a $2.50 price target on the stock. JPMorgan Chase & Co. lowered Amneal Pharmaceuticals from a “neutral” rating to an “underweight” rating in a research report on Tuesday, November 12th. Zacks Investment Research cut Amneal Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 23rd. Finally, Leerink Swann downgraded Amneal Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, November 7th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and five have assigned a buy rating to the company’s stock. Amneal Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $9.00.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

Featured Story: Cost of Equity

Want to see what other hedge funds are holding AMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amneal Pharmaceuticals Inc (NYSE:AMRX).

Institutional Ownership by Quarter for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit